Search

Your search keyword '"Annunziata, Christina M."' showing total 559 results
Start Over Author "Annunziata, Christina M."
559 results on '"Annunziata, Christina M."'

2. UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer

Author

Harrington, Brittney S., Kamdar, Rahul, Ning, Franklin, Korrapati, Soumya, Caminear, Michael W., Hernandez, Lidia F., Butcher, Donna, Edmondson, Elijah F., Traficante, Nadia, Hendley, Joy, Gough, Madeline, Rogers, Rebecca, Lourie, Rohan, Shetty, Jyoti, Tran, Bao, Elloumi, Fathi, Abdelmaksoud, Abdalla, Nag, Madhu Lal, Mazan-Mamczarz, Krystyna, House, Carrie D., Hooper, John D., and Annunziata, Christina M.

Published
2023
Full Text
View/download PDF

3. Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

Author

Cole, Christopher B., Morelli, Maria Pia, Fantini, Massimo, Miettinen, Markku, Fetsch, Patricia, Peer, Cody, Figg, William D., Yin, Tyler, Houston, Nicole, McCoy, Ann, Lipkowitz, Stanley, Zimmer, Alexandra, Lee, Jung-min, Pavelova, Miroslava, Villanueva, Erin N., Trewhitt, Kathryn, Solarz, B. Brooke, Fergusson, Maria, Mavroukakis, Sharon A., Zaki, Anjum, Tsang, Kwong Y., Arlen, Philip M., and Annunziata, Christina M.

Published
2023
Full Text
View/download PDF

4. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

Author

Cole, Christopher B., Morelli, Maria Pia, Fantini, Massimo, Miettinen, Markku, Fetsch, Patricia, Peer, Cody, Figg, William D., Yin, Tyler, Houston, Nicole, McCoy, Ann, Lipkowitz, Stanley, Zimmer, Alexandra, Lee, Jung-min, Pavelova, Miroslava, Villanueva, Erin N., Trewhitt, Kathryn, Solarz, B. Brooke, Fergusson, Maria, Mavroukakis, Sharon A., Zaki, Anjum, Tsang, Kwong Y., Arlen, Philip M., and Annunziata, Christina M.

Published
2023
Full Text
View/download PDF

7. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Author

Disis, Mary L, Taylor, Matthew H, Kelly, Karen, Beck, J Thaddeus, Gordon, Michael, Moore, Kathleen M, Patel, Manish R, Chaves, Jorge, Park, Haeseong, Mita, Alain C, Hamilton, Erika P, Annunziata, Christina M, Grote, Hans Juergen, von Heydebreck, Anja, Grewal, Jaspreet, Chand, Vikram, and Gulley, James L

Subjects
Humans, Ovarian Neoplasms, Neoplasm Recurrence, Local, Disease Progression, Antibodies, Monoclonal, Treatment Outcome, Drug Resistance, Neoplasm, Time Factors, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Antineoplastic Agents, Immunological, B7-H1 Antigen, Progression-Free Survival, Antibodies, Monoclonal, Humanized, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

ImportanceCurrent treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy.ObjectiveTo assess the efficacy and safety of avelumab, an anti-programmed death-ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer.Design, setting, and participantsIn an expansion cohort of a phase 1b, open-label study (JAVELIN Solid Tumor), 125 patients with advanced ovarian cancer who had received chemotherapy including a platinum agent were enrolled between November 6, 2013, and August 27, 2015. Statistical analysis was performed from December 31, 2016, to October 9, 2018.InterventionPatients received avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study.Main outcomes and measuresPrespecified end points in this cohort included confirmed best overall response (per Response Evaluation Criteria In Solid Tumors, version 1.1), immune-related best overall response, duration of response, progression-free survival, overall survival, results of programmed death-ligand 1 expression-based analyses, and safety.ResultsA total of 125 women (median age, 62.0 years [range, 27-84 years]) who had received a median of 3 prior lines of treatment (range, 0-10) for advanced disease were enrolled in the study. Patients received avelumab for a median of 2.8 months (range, 0.5-27.4 months), with a median follow-up of 26.6 months (range, 16-38 months). A confirmed objective response occurred in 12 patients (9.6%; 95% CI, 5.1%-16.2%), including a complete response in 1 patient (0.8%) and a partial response in 11 patients (8.8%). The 1-year progression-free survival rate was 10.2% (95% CI, 5.4%-16.7%) and median overall survival was 11.2 months (95% CI, 8.7-15.4 months). Infusion-related reactions occurred in 25 patients (20.0%). Other frequent treatment-related adverse events (any grade event occurring in ≥10% of patients) were fatigue (17 [13.6%]), diarrhea (15 [12.0%]), and nausea (14 [11.2%]). Grade 3 or higher treatment-related adverse events occurred in 9 patients (7.2%), of which only the level of lipase increased (3 [2.4%]) occurred in more than 1 patient. Twenty-one patients (16.8%) had an immune-related adverse event of any grade. No treatment-related deaths occurred.Conclusions and relevanceAvelumab demonstrated antitumor activity and acceptable safety in heavily pretreated patients with recurrent or refractory ovarian cancer.Trial registrationClinicalTrials.gov identifier: NCT01772004.

Published
2019

9. SMAC mimetics synergize with HDAC inhibitors through by enhancing autocrine TNF-alpha signaling

Author

Shibuya, Yusuke, primary, Kudo, Kei, additional, Zeligs, Kristen P., additional, Anderson, David, additional, Hernandez, Lidia, additional, Ning, Franklin, additional, Cole, Christopher B., additional, Fergusson, Maria, additional, Kedei, Noemi, additional, Lyons, John, additional, Taylor, Jason, additional, Korrapati, Soumya, additional, and Annunziata, Christina M., additional

Published
2024
Full Text
View/download PDF

10. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.

Author

Higham, Christine S, Steinberg, Seth M, Dombi, Eva, Perry, Arie, Helman, Lee J, Schuetze, Scott M, Ludwig, Joseph A, Staddon, Arthur, Milhem, Mohammed M, Rushing, Daniel, Jones, Robin L, Livingston, Michael, Goldman, Stewart, Moertel, Christopher, Wagner, Lars, Janhofer, David, Annunziata, Christina M, Reinke, Denise, Long, Lauren, Viskochil, David, Baker, Larry, and Widemann, Brigitte C

Subjects
Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Background:Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant peripheral nerve sheath tumors (MPNST) has been reported. Methods:We evaluated the objective response (OR) rate of patients with AJCC Stage III/IV chemotherapy-naive NF1 MPNST versus sporadic MPNST after 4 cycles of neoadjuvant chemotherapy, 2 cycles of ifosfamide/doxorubicin, and 2 cycles of ifosfamide/etoposide. A Simon optimal two-stage design was used (target response rate 40%). Results:34 NF1 (median age 33 years) and 14 sporadic (median age 40 years) MPNST patients enrolled. Five of 28 (17.9%) evaluable NF1 MPNST patients had a partial response (PR), as did 4 of 9 (44.4%) patients with sporadic MPNST. Stable disease (SD) was achieved in 22 NF1 and 4 sporadic MPNST patients. In both strata, results in the initial stages met criteria for expansion of enrollment. Only 1 additional PR was observed in the expanded NF1 stratum. Enrollment was slower than expected and the trial closed before full accrual. Conclusions:This trial was not powered to detect differences in response rates between NF1 and sporadic MPNST. While the OR rate was lower in NF1 compared to sporadic MPNST, qualitative responses were similar, and disease stabilization was achieved in most patients.

Published
2017

14. Rapid image deconvolution and multiview fusion for optical microscopy

Author

Guo, Min, Li, Yue, Su, Yijun, Lambert, Talley, Nogare, Damian Dalle, Moyle, Mark W., Duncan, Leighton H., Ikegami, Richard, Santella, Anthony, Rey-Suarez, Ivan, Green, Daniel, Beiriger, Anastasia, Chen, Jiji, Vishwasrao, Harshad, Ganesan, Sundar, Prince, Victoria, Waters, Jennifer C., Annunziata, Christina M., Hafner, Markus, Mohler, William A., Chitnis, Ajay B., Upadhyaya, Arpita, Usdin, Ted B., Bao, Zhirong, Colón-Ramos, Daniel, La Riviere, Patrick, Liu, Huafeng, Wu, Yicong, and Shroff, Hari

Published
2020
Full Text
View/download PDF

19. A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Author

Atkins, Sarah L P, primary, Greer, Yoshimi Endo, additional, Jenkins, Sarah, additional, Gatti-Mays, Margaret E, additional, Houston, Nicole, additional, Lee, Sunmin, additional, Lee, Min-Jung, additional, Rastogi, Shraddha, additional, Sato, Nahoko, additional, Burks, Christina, additional, Annunziata, Christina M, additional, Lee, Jung-Min, additional, Nagashima, Kunio, additional, Trepel, Jane B, additional, Lipkowitz, Stanley, additional, and Zimmer, Alexandra S, additional

Published
2023
Full Text
View/download PDF

20. Data from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

Author

Greer, Yoshimi Endo, primary, Hernandez, Lidia, primary, Fennell, Emily M.J., primary, Kundu, Manjari, primary, Voeller, Donna, primary, Chari, Raj, primary, Gilbert, Samuel F., primary, Gilbert, Thomas S.K., primary, Ratnayake, Shashikala, primary, Tang, Binwu, primary, Hafner, Markus, primary, Chen, Qingrong, primary, Meerzaman, Daoud, primary, Iwanowicz, Edwin, primary, Annunziata, Christina M., primary, Graves, Lee M., primary, and Lipkowitz, Stanley, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table S2 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

Author

Greer, Yoshimi Endo, primary, Hernandez, Lidia, primary, Fennell, Emily M.J., primary, Kundu, Manjari, primary, Voeller, Donna, primary, Chari, Raj, primary, Gilbert, Samuel F., primary, Gilbert, Thomas S.K., primary, Ratnayake, Shashikala, primary, Tang, Binwu, primary, Hafner, Markus, primary, Chen, Qingrong, primary, Meerzaman, Daoud, primary, Iwanowicz, Edwin, primary, Annunziata, Christina M., primary, Graves, Lee M., primary, and Lipkowitz, Stanley, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure S1 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

Author

Greer, Yoshimi Endo, primary, Hernandez, Lidia, primary, Fennell, Emily M.J., primary, Kundu, Manjari, primary, Voeller, Donna, primary, Chari, Raj, primary, Gilbert, Samuel F., primary, Gilbert, Thomas S.K., primary, Ratnayake, Shashikala, primary, Tang, Binwu, primary, Hafner, Markus, primary, Chen, Qingrong, primary, Meerzaman, Daoud, primary, Iwanowicz, Edwin, primary, Annunziata, Christina M., primary, Graves, Lee M., primary, and Lipkowitz, Stanley, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Methods and References from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis

Author

Greer, Yoshimi Endo, primary, Hernandez, Lidia, primary, Fennell, Emily M.J., primary, Kundu, Manjari, primary, Voeller, Donna, primary, Chari, Raj, primary, Gilbert, Samuel F., primary, Gilbert, Thomas S.K., primary, Ratnayake, Shashikala, primary, Tang, Binwu, primary, Hafner, Markus, primary, Chen, Qingrong, primary, Meerzaman, Daoud, primary, Iwanowicz, Edwin, primary, Annunziata, Christina M., primary, Graves, Lee M., primary, and Lipkowitz, Stanley, primary

Published
2023
Full Text
View/download PDF

26. Overcoming the challenges of drug development in platinumresistant ovarian cancer.

Author

Eskander, Ramez N., Moore, Kathleen N., Monk, Bradley J., Herzog, Thomas J., Annunziata, Christina M., O'Malley, David M., and Coleman, Robert L.

Subjects
OVARIAN cancer, DRUG development, CLINICAL trials, IMMUNE checkpoint inhibitors, HEMATOLOGIC malignancies, GYNECOLOGIC cancer
Abstract

The definition of "platinum-resistant ovarian cancer" has evolved; it now also reflects cancers for which platinum treatment is no longer an option. Standard of care for platinum-resistant ovarian cancer is single-agent, non-platinum chemotherapy with or without bevacizumab, which produces modest response rates, with the greatest benefits achieved using weekly paclitaxel. Several recent phase 3 trials of pretreated patients with prior bevacizumab exposure failed to meet their primary efficacy endpoints, highlighting the challenge in improving clinical outcomes among these patients. Combination treatment with antiangiogenics has improved outcomes, whereas combination strategies with immune checkpoint inhibitors have yielded modest results. Despite extensive translational research, there has been a lack of reliable and established biomarkers that predict treatment response in platinum-resistant ovarian cancer. Additionally, in the platinum-resistant setting, implications for the time between the penultimate dose of platinum therapy and platinum retreatment remain an area of debate. Addressing the unmet need for an effective treatment in the platinum-resistant setting requires thoughtful clinical trial design based on a growing understanding of the disease. Recent cancer drug approvals highlight the value of incorporating molecular phenotypes to better define patients who are more likely to respond to novel therapies. Clinical trials designed per the Gynecologic Cancer InterGroup recommendations--which advocate against relying solely upon the platinum-free interval--will help advance our understanding of recurrent ovarian cancer response where platinum rechallenge in the platinum-resistant setting may be considered. The inclusion of biomarkers in clinical trials will improve patient stratification and potentially demonstrate correlations with biomarker expression and duration of response. With the efficacy of antibody-drug conjugates shown for the treatment of some solid and hematologic cancers, current trials are evaluating the use of various novel conjugates in the setting of platinum-resistant ovarian cancer. Emerging novel treatments coupled with combination trials and Frontiers in Oncology frontiersin. biomarker explorations offer encouraging results for potential strategies to improve response rates and prolong progression-free survival in this population with high unmet need. This review outlines existing data from contemporary clinical trials of patients with platinum-resistant ovarian cancer and suggests historical synthetic benchmarks for non-randomized trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors

Author

Weiss, Jonathan M., Davies, Luke C., Karwan, Megan, Ileva, Lilia, Ozaki, Michelle K., Cheng, Robert Y.S., Ridnour, Lisa A., Annunziata, Christina M., Wink, David A., and McVicar, Daniel W.

Subjects
Cancer treatment -- Innovations, Macrophages -- Health aspects, Cell metabolism -- Health aspects, Carboxylic acids -- Health aspects, Peritoneal diseases -- Development and progression -- Care and treatment, Health care industry
Abstract

Control of cellular metabolism is critical for efficient cell function, although little is known about the interplay between cell subset-specific metabolites in situ, especially in the tumor setting. Here, we determined how a macrophage-specific (M[phi]-specific) metabolite, itaconic acid, can regulate tumor progression in the peritoneum. We show that peritoneal tumors (B16 melanoma or ID8 ovarian carcinoma) elicited a fatty acid oxidation-mediated increase in oxidative phosphorylation (OXPHOS) and glycolysis in peritoneal tissue-resident macrophages (pResM[phi]). Unbiased metabolomics identified itaconic acid, the product of immune-responsive gene 1-mediated (Irg1-mediated) catabolism of mitochondrial c/s-aconitate, among the most highly upregulated metabolites in pResM[phi] of tumor-bearing mice. Administration of lentivirally encoded Irg1 shRNA significantly reduced peritoneal tumors. This resulted in reductions in OXPHOS and OXPHOS-driven production of ROS in pResM[phi] and ROS-mediated MAPK activation in tumor cells. Our findings demonstrate that tumors profoundly alter pResM[phi] metabolism, leading to the production of itaconic acid, which potentiates tumor growth. Monocytes isolated from ovarian carcinoma patients' ascites fluid expressed significantly elevated levels of IRG1. Therefore, IRG1 in pResM[phi] represents a potential therapeutic target for peritoneal tumors., Introduction The peritoneal cavity is a frequent site of tumor development and metastasis. Ovarian epithelial cancer often spreads to the peritoneal cavity and is treated similarly to primary peritoneal cancer [...]

Published
2018
Full Text
View/download PDF

28. Supplementary Information from Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers

Author

Zhang, Jialing, primary, Chen, Tony, primary, Yang, Xinping, primary, Cheng, Hui, primary, Späth, Stephan S., primary, Clavijo, Paul E., primary, Chen, Jianhong, primary, Silvin, Christopher, primary, Issaeva, Natalia, primary, Su, Xiulan, primary, Yarbrough, Wendell G., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

29. Data from NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells

Author

House, Carrie D., primary, Jordan, Elizabeth, primary, Hernandez, Lidia, primary, Ozaki, Michelle, primary, James, Jana M., primary, Kim, Marianne, primary, Kruhlak, Michael J., primary, Batchelor, Eric, primary, Elloumi, Fathi, primary, Cam, Margaret C., primary, and Annunziata, Christina M., primary

Published
2023
Full Text
View/download PDF

30. Supplemental Table 2 from NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells

Author

House, Carrie D., primary, Jordan, Elizabeth, primary, Hernandez, Lidia, primary, Ozaki, Michelle, primary, James, Jana M., primary, Kim, Marianne, primary, Kruhlak, Michael J., primary, Batchelor, Eric, primary, Elloumi, Fathi, primary, Cam, Margaret C., primary, and Annunziata, Christina M., primary

Published
2023
Full Text
View/download PDF

31. Supplemental Table 1 from Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers

Author

Zhang, Jialing, primary, Chen, Tony, primary, Yang, Xinping, primary, Cheng, Hui, primary, Späth, Stephan S., primary, Clavijo, Paul E., primary, Chen, Jianhong, primary, Silvin, Christopher, primary, Issaeva, Natalia, primary, Su, Xiulan, primary, Yarbrough, Wendell G., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

32. Supplemental Table 2 from SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2

Author

Eytan, Danielle F., primary, Snow, Grace E., primary, Carlson, Sophie, primary, Derakhshan, Adeeb, primary, Saleh, Anthony, primary, Schiltz, Stephen, primary, Cheng, Hui, primary, Mohan, Suresh, primary, Cornelius, Shaleeka, primary, Coupar, Jamie, primary, Sowers, Anastasia L., primary, Hernandez, Lidia, primary, Mitchell, James B., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

33. Data from SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2

Author

Eytan, Danielle F., primary, Snow, Grace E., primary, Carlson, Sophie, primary, Derakhshan, Adeeb, primary, Saleh, Anthony, primary, Schiltz, Stephen, primary, Cheng, Hui, primary, Mohan, Suresh, primary, Cornelius, Shaleeka, primary, Coupar, Jamie, primary, Sowers, Anastasia L., primary, Hernandez, Lidia, primary, Mitchell, James B., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

34. Data from Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers

Author

Zhang, Jialing, primary, Chen, Tony, primary, Yang, Xinping, primary, Cheng, Hui, primary, Späth, Stephan S., primary, Clavijo, Paul E., primary, Chen, Jianhong, primary, Silvin, Christopher, primary, Issaeva, Natalia, primary, Su, Xiulan, primary, Yarbrough, Wendell G., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

35. Supplemental Table 2 from Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers

Author

Zhang, Jialing, primary, Chen, Tony, primary, Yang, Xinping, primary, Cheng, Hui, primary, Späth, Stephan S., primary, Clavijo, Paul E., primary, Chen, Jianhong, primary, Silvin, Christopher, primary, Issaeva, Natalia, primary, Su, Xiulan, primary, Yarbrough, Wendell G., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

36. Supplemental Figure 1 from NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells

Author

House, Carrie D., primary, Jordan, Elizabeth, primary, Hernandez, Lidia, primary, Ozaki, Michelle, primary, James, Jana M., primary, Kim, Marianne, primary, Kruhlak, Michael J., primary, Batchelor, Eric, primary, Elloumi, Fathi, primary, Cam, Margaret C., primary, and Annunziata, Christina M., primary

Published
2023
Full Text
View/download PDF

37. Supplemental Figures from SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2

Author

Eytan, Danielle F., primary, Snow, Grace E., primary, Carlson, Sophie, primary, Derakhshan, Adeeb, primary, Saleh, Anthony, primary, Schiltz, Stephen, primary, Cheng, Hui, primary, Mohan, Suresh, primary, Cornelius, Shaleeka, primary, Coupar, Jamie, primary, Sowers, Anastasia L., primary, Hernandez, Lidia, primary, Mitchell, James B., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Author

Lampert, Erika J., primary, Zimmer, Alexandra, primary, Padget, Michelle, primary, Cimino-Mathews, Ashley, primary, Nair, Jayakumar R., primary, Liu, Yingmiao, primary, Swisher, Elizabeth M., primary, Hodge, James W., primary, Nixon, Andrew B., primary, Nichols, Erin, primary, Bagheri, Mohammad H., primary, Levy, Elliott, primary, Radke, Marc R., primary, Lipkowitz, Stanley, primary, Annunziata, Christina M., primary, Taube, Janis M., primary, Steinberg, Seth M., primary, and Lee, Jung-Min, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table 1 from Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Author

Lee, Jung-Min, primary, Peer, Cody J., primary, Yu, Minshu, primary, Amable, Lauren, primary, Gordon, Nicolas, primary, Annunziata, Christina M., primary, Houston, Nicole, primary, Goey, Andrew K.L., primary, Sissung, Tristan M., primary, Parker, Bernard, primary, Minasian, Lori, primary, Chiou, Victoria L., primary, Murphy, Robert F., primary, Widemann, Brigitte C., primary, Figg, William D., primary, and Kohn, Elise C., primary

Published
2023
Full Text
View/download PDF

40. Suplementary Methods from SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2

Author

Eytan, Danielle F., primary, Snow, Grace E., primary, Carlson, Sophie, primary, Derakhshan, Adeeb, primary, Saleh, Anthony, primary, Schiltz, Stephen, primary, Cheng, Hui, primary, Mohan, Suresh, primary, Cornelius, Shaleeka, primary, Coupar, Jamie, primary, Sowers, Anastasia L., primary, Hernandez, Lidia, primary, Mitchell, James B., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Data from Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Author

Lee, Jung-Min, primary, Peer, Cody J., primary, Yu, Minshu, primary, Amable, Lauren, primary, Gordon, Nicolas, primary, Annunziata, Christina M., primary, Houston, Nicole, primary, Goey, Andrew K.L., primary, Sissung, Tristan M., primary, Parker, Bernard, primary, Minasian, Lori, primary, Chiou, Victoria L., primary, Murphy, Robert F., primary, Widemann, Brigitte C., primary, Figg, William D., primary, and Kohn, Elise C., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data from Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

Author

Annunziata, Christina M., primary, Walker, Amanda J., primary, Minasian, Lori, primary, Yu, Minshu, primary, Kotz, Herbert, primary, Wood, Bradford J., primary, Calvo, Katherine, primary, Choyke, Peter, primary, Kimm, Daniel, primary, Steinberg, Seth M., primary, and Kohn, Elise C., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 1 from NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells

Author

House, Carrie D., primary, Jordan, Elizabeth, primary, Hernandez, Lidia, primary, Ozaki, Michelle, primary, James, Jana M., primary, Kim, Marianne, primary, Kruhlak, Michael J., primary, Batchelor, Eric, primary, Elloumi, Fathi, primary, Cam, Margaret C., primary, and Annunziata, Christina M., primary

Published
2023
Full Text
View/download PDF

44. Supplemental Experimental Procedures from NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells

Author

House, Carrie D., primary, Jordan, Elizabeth, primary, Hernandez, Lidia, primary, Ozaki, Michelle, primary, James, Jana M., primary, Kim, Marianne, primary, Kruhlak, Michael J., primary, Batchelor, Eric, primary, Elloumi, Fathi, primary, Cam, Margaret C., primary, and Annunziata, Christina M., primary

Published
2023
Full Text
View/download PDF

45. Supplemental Table 1 from SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2

Author

Eytan, Danielle F., primary, Snow, Grace E., primary, Carlson, Sophie, primary, Derakhshan, Adeeb, primary, Saleh, Anthony, primary, Schiltz, Stephen, primary, Cheng, Hui, primary, Mohan, Suresh, primary, Cornelius, Shaleeka, primary, Coupar, Jamie, primary, Sowers, Anastasia L., primary, Hernandez, Lidia, primary, Mitchell, James B., primary, Annunziata, Christina M., primary, Chen, Zhong, primary, and Van Waes, Carter, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results